
The Roundup: Top Takeaways from Oaktree’s Quarterly Letters – June 2023 Edition
The Insight by Oaktree Capital
The Future of Life Sciences Lending
The outlook for Life Sciences lending has long been positive. The current combination of strong underlying fundamentals, limited financing options, and deflated valuations has made the prognosis even better. In early 2023, retail investors' concerns about deteriorating credit quality in the loan market have appeared to outweigh the appeal of rising yields which now top 10% on average.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.